Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors on major liver outcomes in metabolic dysfunction‐associated steatotic liver disease
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15853 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Tsung-Hua Shen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Care & Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aim
To compare the effectiveness of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2is) with dipeptidyl peptidase‐4 inhibitors (DPP4is) on major liver outcomes (MLO) in patients with type 2 diabetes (T2D) and metabolic dysfunction‐associated steatotic liver disease (MASLD). Materials and Methods We included adult patients with T2D and MASLD, using metformin without specific liver conditions or surgeries, from the Merative MarketScan database. Patients initiating SGLT2is or DPP4is from 1 January 2014 to 31 December 2022 were identified. The primary outcome was time to MLO diagnosis. Overlap weighting balanced covariates, integrated with a Cox proportional hazards model for survival analysis.
Results
Among 44 651 patients, 22 100 initiated SGLT2is, and 22 551 began DPP4is. After weighting, the incidence rate of MLO in the SGLT2i group was 3.8 per 1000 person‐years, and it was 3.9 per 1000 person‐years in the DPP4i group, resulting in an adjusted hazard ratio (aHR) of 0.82 (95% CI, 0.60‐1.10). SGLT2i initiation was not associated with cirrhosis (aHR: 0.77; 95% CI, 0.55‐1.06) or hepatocellular carcinoma (aHR: 0.99; 95% CI, 0.47‐1.83) separately. Subgroup and sensitivity analyses did not yield significant results.
Conclusions
In patients with T2D and MASLD, SGLT2is did not show a lower risk of MLO compared with DPP4is. Clinicians should consider the overall patient conditions and the additional benefits of SGLT2is to support the decision to switch from DPP4is.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Care & Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
- Social and Administrative Pharmacy Program, Department of Pharmaceutical Care & Health System, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, Minnesota, USA.
- Division of Biostatistics & Health Data Science, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
ORCID-Profile: Tsung-Hua Shen
Zitieren
APA
Shen, T. H., Aby, E. S., Vock, D., & Farley, J. F. (2024). Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors on major liver outcomes in metabolic dysfunction‐associated steatotic liver disease. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15853
Vancouver
Shen TH, Aby ES, Vock D, Farley JF. Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors on major liver outcomes in metabolic dysfunction‐associated steatotic liver disease. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15853
BibTeX
@article{Shen2024,
author = {Shen, Tsung-Hua and Aby, Elizabeth S and Vock, David and Farley, Joel F},
title = {Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors on major liver outcomes in metabolic dysfunction‐associated steatotic liver disease},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15853}
}
EUVIMED